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Insertion of foreign oligopeptide sequences (4G50 amino acids in length) into the Pro144 position of hepatitis B core antigen (HBcAg) leads to 
the formation of chimeric capsids in Escherichia co/i cells. These capsids are morphologically and immunogically similar to native HBcAg, but 
expose the inserted oligopeptides on their outer surface and exhibit antigenic and immunogenic haracteristics of the latter. As a source of model 
antigenic determinants, the appropriate DNA copies excised from cloned viral genes uch as the pm-S region of hepatitis B virus, the transmembrane 
protein gp41 of human immunodeficiency virus 1 and the envelope protein gp51 of bovine leukemia virus have been used. The localization of the 
inserted antigenic determinants on the surface of chimeric capsids does not depend on the presence or absence of the arginine-rich, 39 amino acid- 
long C terminus of HBcAg. 
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1. INTRODUCTION 
Expression of the core antigen (HBcAg) gene of hep- 
atitis B virus (HBV) in Escherichia coli leads to the 
highly efficient synthesis of capsids, 25-27 nm in diam- 
eter, that are morphologically and immunologically in- 
distinguishable from viral core particles [l-4]. Recent- 
ly, the usefulness of recombinant HBcAg as a carrier 
for foreign oligopeptide sequences has been suggested 
[5-81. Furthermore, we have constructed special vec- 
tors, so-called ‘exposing vectors’ [5,7] for insertion of 
the synthetic or natural DNA fragments coding for 
functionally important oligopeptides (e.g. antigenic 
determinants, peptide hormones, etc.) into preselected 
points of the HBcAg gene. The peptide sequences in- 
serted at these points should (i) expose themselves on 
the outer surface of the capsid; (ii) preserve their native 
conformation and thus their antigenic and immuno- 
genic properties; and (iii) preserve the capsid-forming 
ability of chimeras. 
The most prospective in terms of preserving the 
capsid-forming ability seems to be the position 144 
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(ProiM) [5] that lies close to the processing point (Thr147 
or Vali49) of C polypeptide [9]. Such processing in- 
volves splitting off of the 34-36 amino-acid-long (sub- 
type ayw) arginine-rich C terminus of HBcAg and re- 
sults in the formation of hepatitis B-e antigen (HBeAg), 
not found to form capsid structures in vivo [9]. How- 
ever, expression of a truncated HBeAg-like gene in E. 
coli leads to the efficient synthesis of self-assembled 
particles that are morphologically very similar to 
HBcAg capsids [5,7]. Moreover, direct analysis of 
HBcAg capsids by high resolution “N-NMR spectro- 
scopy and monoclonal antibody mapping indicates the 
high spatial mobility and exterior localization of the C- 
terminal arginine-rich part of the molecule [lo]. 
Here we report first immunological evidence for 
outer exposure of foreign antigenic determinants in- 
serted into position Pro14 of the HBcAg gene. Dif- 
ferent viral gene fragments coding for well- 
characterized antigenic determinants from such pro- 
teins as the pre-S region of HBV, transmembrane pro- 
tein gp41 of human immunodeficiency virus 1 (HIV-l), 
envelope protein gp51 of bovine leukemia virus (BLV), 
were chosen as model objects. The appropriate DNA 
fragments were excised from cloned viral genomes and 
inserted into the polylinker sequence positioned be- 
tween Pro144 and Glui45 in the exposing vector. 
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2. EXPERIMENTAL 
Recombinant plasmids were constructed by a combination of 
standard techniques on the basis of exposing vector pHBcl315, which 
contains the HBcAg gene controlled by the trp promoter and has (i) 
an optimized translation initiation region; and (ii) a polylinker se- 
quence (EcoRV-CluI-PvuI) coding for 12 amino acids (KRSISKRS- 
1SIS) and inserted at the MspI site which overlaps the Pro144 codon 
171. The following genomes served as sources of viral sequences: 
HBV, subtype ayw [11.12], BLV [13], HIV-l 1141. The construction 
strategy is shown in fig. 1. Cultures of E. coii strain K802 harboring 
the aapropriate plasmids were grown by shaking overnight at 37°C to 
an ODssa of 4.0 in Casamino acid medium, The bacteria were lysed 
by lysozyme treatment and capsids were purified by Sepharose CL4B 
chromatography. 
The molecular masses of chimeric polypeptides were determined by 
standard immunoblotting procedure after Laemmli’s SDS-PAGE 
separation. Human polyclonal or murine monoclonal anti-HBc anti- 
bodies [lo], monoclonal anti-preS1 MAl8/7 [15], anti-preS2 mAb E 
and mAb F [la], anti-gp41 mAb 3D6 [17], anti-gp51 MAK14 1181 
were used. The antigenicity of inserted epitopes was measured by two 
different ELISA variants when purified chimeric capsids or human or 
mouse anti-HBc were absorbed on the solid phase. 
For electron microscopy, the samples were negatively stained with 
1% aqueous uranyl acetate or 2% phosphotungstic acid and examin- 
ed in a JEM IOOB electron microscope at an accelerating voltage of 
80 kV and a screen magni~cation of 1~~ x . Immunogold electron 
microscopy was carried out as described 1191. 
DNA sequences were determined by the Sanger technique using 
synthetic oligonucleotide primers. 
3. RESULTS AND DISCUSSION 
Fig.1 shows the constructed chimeras with foreign 
oligopeptides inserted at Pro144 of HBcAg. Two vari- 
ants of protein design are examined: (i) conserving the 
arginine-rich C terminus of the carrier molecule; and 
(ii) removing it. In all cases the inserted sequences are 
similar in size, appro~mately 40-50 amino acids, but 
vary strongly in their primary and also in predicted sec- 
ondary structure (not shown). 
HBcAg 
“exposing vector” 
(HBc1315) 
HBc-p&31, 
HBcA-p&l, 
HBc-preS1 b 
HBc - pr% S2 
HBcA-pm32 
H&A-fWfgp51 
HBc-HIV gp41 
H&A- HIVgp41 
Eco RV C/s I 
Fig.1. The principal scheme for construction of chimeric structures 
using HBcAg as a carrier. 
The yield of chimeric polypeptides synthesized in E. 
co/i cells resembles that of wild-type HBcAg and con- 
stitutes lo-25% of the total cellular protein. The 
chimeric products have the expected length for the 
given constructions (not shown) and appear exclusively 
in capsid-like particles already undergoing self- 
assembly in host cells (fig.2). Chimeric capsids are 
similar in their shape and diameter (about 25 nm) to in- 
itial HBcAg and differ from it only very slightly. They 
possess normal HBc-antigenicity, appearing as a com- 
plete coincidence of immunoprecipitation lines in the 
Ouchterlony double-diffusion test against human anti- 
HBc antibodies (not shown). 
Selection of potential antigenic inserts was made on 
the basis of their practical importance as a possible 
source for diagnostics and vaccines. The latter is 
especially intriguing because our carrier particles har- 
boring HBc- and HBe-antigenicity are potentially pro- 
Fig.2. Electron microscopic analysis of chimeric capsids on the basis of HBcAg. (A) control (wild-type HBcAg); (B) HBcd-preS1,; (C) HBc-preS2; 
(D) HBcA-preS2; (E) HBcA-BLVgp51; (F) HBc-HIVgp41. Magnification 5~~ x . White bar 10 nm. 
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Table 1 
Antigenic properties of chimeric HBcAg capsids in ELISA assay 
Capsids absorbed P/N’ ratio 
on the solid phase with subsequent monoclonal antibodies 
Anti- Anti Anti- Anti- Anti- 
HBc preS1 preS2 gp41 gP5 1 
HBcAg 
HBc-preS1, 
HBc&preS1, 
HBc-preSl6 
HBc-preS2 
HBcA-preS2 
HBc-HIVgp41 
HBcA-BLVgpSl 
21 1 2 1 1 
20 28 1 NDb ND 
20 25 1 1 1 
19 1 1 ND ND 
20 1 21 1 1 
20 1 22 ND ND 
18 ND ND 23 ND 
18 ND ND ND 45 
a Absorbance A.w ratio of specimens measured (P) and negative con- 
trol (N) 
b ND, not determined 
HBc, which selectively recognizes only conformational 
HBc-epitopes. Nevertheless, antigenic properties of 
chimeras differed only slightly from those listed in table 
1. 
Further evidence for the surface localization of in- 
serted oligopeptides was obtained by using immunogold 
electron microscopy (fig.3). Anti-species antibodies, 
labelled with colloidal gold, formed a typical halo 
around capsids that were able to bind the appropriate 
anti-epitope antibodies. 
Chimeric capsids possess not only antigenic but also 
immunogenic properties of inserted sequences. After 
immunization of rabbits, both anti-HBc and anti- 
epitope antibodies have been found (fig.4). The level of 
anti-HBc immune responses in all cases corresponds to 
that obtained in a control after immunization with 
HBcAg. However, the titers of anti-epitope antibodies 
Fig.3. Immunogold electron microscopy of HBcAg chimeras. (A) HBcA-preS1, + anti-preS1 1 
HBcAg + MA1817 (control). Magnification 500000 x . Bar 10 nm. 
MA18/7; (B) HBc-preS2 + anti-preS2 mAb E; ((7) 
tective in immunization against hepatitis B [20]. 
Moreover, HBcAg can serve as a T-cell and B-cell im- 
munogen and shows high efficiency of T-cell priming 
[21]. Our choice of antigens was influenced also by the 
availability of well-characterized monoclonal an- 
tibodies directed against sequential epitopes of preS, 
gp51 and gp41 proteins. These antibodies were used to 
localize the inserted oligopeptides on the surface of 
HBcAg capsids. 
When examined with the immunoblot technique, 
chimeric polypeptides displayed not only standard 
HBc-antigenicity (with monoclonal anti-HBc targeted 
to sequential epitopes), but also the expected antigenici- 
ty of oligopeptides inserted with the appropriate mono- 
clonal antibodies (see section 2). 
Chimeric capsids, when absorbed on solid phase in 
ELISA assay, are recognized equally well not only by 
anti-HBc (monoclonal or polyclonal, conformational 
or sequential) but also by corresponding antibodies 
directed against he inserted epitopes (anti-epitope anti- 
bodies) (table 1). 
To more reliably confirm the external positioning of 
inserted epitopes on the surface of native chimeric cap- 
sids, we have used an alternative ELISA technique, 
which restricted the absorption of non-assembled pro- 
tein. The solid phase was coated in this case with anti- 
are markedly lower. Moreover, the inserted oligopep- 
tides show different immunogenicity despite the equal 
HBc-immunogenicity of chimeric capsids. Although 
chimeras present multiple copies of inserted oligopep- 
tides on their surface, the appropriate immune 
responses in rabbits are lower than expected. Ex- 
periments to clarify this discrepancy are in progress. 
p/N1 
60 
t 
60 
-3 4 -5 -ii 
Log [serum dilution] 
Fig.4. Immunogenic properties of HBcAg chimeras. HBc-preS pro- 
teins are shown as an example: HBc-immunogenicity as broken 
lines, preS-immunogenicity as solid lines. The following antigens 
were used for immunization: HBC-p&lb (0), HBcA-preS2 (O), 
HBcAg (A). 
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In conclusion, HBcAg may serve as a carrier for 
foreign oligopeptide sequences of medium size, at least 
40-50 amino acids long. These oligopeptides can be in- 
serted into HBcAg before the arginine-rich C terminus 
or replace the latter without (i) influence on carrier self- 
assembly; or (ii) distortion of native conformation of 
inserted oligopeptides. This new approach could be us- 
ed to create prospective immunodiagnostic reagents and 
polyfunctional vaccines against diseases of different 
etiology. 
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